Blow To Ipsen As FerGene Nabs CEO Meek
Bad Timing For French Firm
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.
You may also be interested in...
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
Sales grew 9.6% at Ipsen in the first quarter, and the search for a new CEO is on track, but France’s specialty pharmaceutical company maintained its 2020 guidance suspension because of the uncertainty over the course of the COVID-19 pandemic.
The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.